Led · Equity · May 2026

iFAST Diagnostics is developing the iFAST One, an ultra-rapid antimicrobial susceptibility test system that leverages impedance flow cytometry to measure electrical properties of bacteria from positive blood culture samples. The platform can provide AST results in less than three hours and is priced comparably to the standard of care. The company received the UK Conformity Assessed (UKCA) mark for the system earlier this year. To support commercialization, iFAST closed a £5 million financing round and obtained a £2.1 million non-dilutive loan from Innovate UK. The new funding is earmarked to expand UK rollout, pursue EU regulatory approval, and accelerate regulatory and clinical programs in the US.

Participated · Series A · Mar 2026

JAAQ operates a digital health engagement platform built around a clinically governed content library and an AI infrastructure layer. Its library contains more than 10,000 expert-led and lived-experience videos, and its AI-powered journeys are designed to integrate into existing user, patient, and customer digital experiences. The platform is deployed across organizations covering more than 1.5 million eligible lives. JAAQ offers both direct integration into partners' digital journeys and a hosted experience tailored to users. The company is investing in engineering to enable AI-native products that combine conversational AI with video to deliver personalized behavioral health pathways. Leadership additions include Alex Packham as CEO and Saurabh Johri leading product and technology development. JAAQ is expanding across the UK and U.S., targeting large employers, insurers, and healthcare systems, and recently raised $17 million to support that growth.

Led · Seed · Feb 2026

Klaris develops software that uses artificial intelligence to analyse and automate compliance and consistency checks across medical-device technical documentation, helping manufacturers identify gaps, stay aligned with MDR, IVDR and FDA requirements, and prepare submissions and audits. By replacing manual processes with automated workflows, the platform improves traceability, data security and efficiency throughout the product lifecycle. Founded by Francesco Corazza and Mihai-Sorin Dobre, the London-based startup has already gained initial commercial traction in the UK and Italy. Klaris plans to leverage its regulatory framework library and expert validations to expand across the wider EU market, where growing compliance demands are squeezing device availability and R&D budgets. The company’s addressable market is large: the global medical-device sector is projected to top $1.1 trillion by 2034, yet a high proportion of 510(k) submissions still suffer quality deficiencies. Klaris recently secured $1 million in pre-seed funding, giving it capital to scale its engineering and product teams and accelerate European expansion. No revenue or user figures were disclosed in the article.

Led · Equity · Dec 2024

52North is a Cambridge, UK-based med-tech company developing low-cost products to streamline urgent care pathways in oncology and improve patient safety across socio-economic groups. Its flagship product, Neutrocheck®, was granted breakthrough status by the UK Government under the Innovative Devices Access Pathway earlier this year. The company's products are still in development, have not been authorised by regulators and are not currently available for sale. 52North plans to use the £4.72M in newly raised funding to advance its products toward market. Founded in 2018 by University of Cambridge postgraduates, the company focuses on urgent care pathways in oncology. 52North, founded in 2018 and based in Cambridge, develops Neutrocheck, a portable device plus app that enables cancer patients to test their risk of life-threatening neutropenic sepsis at home or in clinical settings. The company’s mission is to improve health outcomes and health equity by reinventing care pathways. 52North was named Medtech Company of the Year at the 2023 Cambridge Independent Science & Technology Awards. It has joined two major US accelerator programmes — Cedars‑Sinai and Texas Medical Centre — and is participating in a US incubator to drive international expansion. Participation in those programmes, funded in part by Innovate UK’s Global Business Incubator programme, has included over 50 mentor interactions with clinicians and insurers to refine the US value proposition. The company has engaged in industry events and collaborations, including presentations at HLTH and the Texas Life Sciences Forum and a new collaboration with Cedars‑Sinai’s Tatonetti Lab; financially it received a $100,000 investment from Cedars‑Sinai alongside other investors. Founded in 2018 and based in the UK, 52 North Health has developed NeutroCheck, a small portable device paired with a digital platform that assesses neutropenic sepsis risk from a blood finger-prick. The solution aims to triage patients at home so at-risk patients are prioritised for urgent care while low-risk patients can avoid unnecessary A&E visits. The company plans to incorporate UnifAI Technology’s AI-powered digital reader into the solution and to progress through its first clinical trial. With a new grant from Innovate UK, the startup will scale development, hit key clinical milestones and prepare for clinical validation. The clinical validation study is expected to begin next summer and involve about 250 patients, followed by an at-home test of the device for around 30 patients. Results will support a regulatory submission for UKCA and CE marking and build evidence to enable NHS roll-out. 52 North Health developed NeutroCheck, a low-cost clinical AI point-of-care device and digital platform for at-home monitoring of neutropenic sepsis risk in cancer patients. The company says NeutroCheck improves safety, quality of life and care pathways by enabling remote monitoring and AI-driven risk prediction. Its platform combines patient and clinician input with predictive models to inform treatment decisions. The startup is women-led and founded in 2018 at the GPS coordinates of Cambridge. 52 North plans to use its recent funding to advance NeutroCheck through U.K. clinical trials and to pursue strategic partnerships with organisations such as the UK Sepsis Trust and Macmillan Cancer Support. The company positions health equity and improved outcomes at the heart of its solutions.

Participated · Series A · Nov 2024

PocDoc develops a proprietary smartphone-based platform that enables patients to perform rapid diagnostic tests for cardiovascular, metabolic and renal screenings in workplaces, communities and at home, delivering fast results. Its flagship 'Healthy Heart Check' allows cardiovascular screenings with results viewable via the NHS app. The company has partnerships with the NHS and private-sector partners including Asda, Pharmacy2U and Lincolnshire Co-op Pharmacy. Tens of thousands of patients have used the service and 97% report they would recommend it to family and friends. PocDoc says it has new tests for metabolic, kidney and whole-body health in the pipeline and plans to scale into new international markets next year. Financially, the company completed a €5.9 million pre-A funding round—the reportedly largest at this stage for a UK digital diagnostics company—which will support rapid growth and commercialization.